238 related articles for article (PubMed ID: 8958806)
1. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
3. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
4. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
5. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Kuźbicki L; Sarnecka A; Chwirot BW
Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
[TBL] [Abstract][Full Text] [Related]
10. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
[TBL] [Abstract][Full Text] [Related]
11. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
Stadler R; Garbe C
Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
[TBL] [Abstract][Full Text] [Related]
12. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
13. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
Pluot M; Joundi A; Grosshans E
Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
16. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
[TBL] [Abstract][Full Text] [Related]
18. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Ohnishi Y; Tajima S; Ishibashi A
Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?
Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T
J Pathol; 1999 May; 188(1):56-62. PubMed ID: 10398141
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
